There is a growing body of evidence from both observational and randomised trials
implicating integrase inhibitors, particularly dolutegravir and bictegravir, with the …

Background ADVANCE compared the efficacy and safety of two antiretroviral first-line
combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil …

Introduction HIV‐1 transmitted drug resistance (TDR) prevalence increased during the initial
years of the antiretroviral therapy (ART) global scale‐up. Few studies have examined recent …

Background Antiretroviral therapy (ART) during pregnancy is important for both maternal
health and prevention of perinatal HIV-1 transmission; however adequate data on the safety …

Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of
second generation integrase inhibitors. We sequenced pretreatment plasma specimens …

Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …

Background Antiretroviral therapy (ART) scale-up in sub-Saharan Africa combined with
weak routine virological monitoring has driven increasing HIV drug resistance. We …

Key updates ÿ A recommendation for dolutegravir (DTG)-based therapies as the preferred
first-line antiretroviral therapy (ART) option (section 11). ÿ Updated guidelines for second …

Objective: Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would
provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir …

Background Eastern Europe and Central Asia (EECA) is one of the regions where the HIV
epidemic continues to grow at a concerning rate. Antiretroviral therapy (ART) coverage in …